Medpace Holdings Inc vs Micron Technology, Inc. — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Micron Technology, Inc. trades at $1,029 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 69.6× Medpace Holdings Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Micron Technology, Inc. for 48 Days on average.
| MEDP | MU | |
|---|---|---|
Market Cap | $16.82B | $1.17T |
Volume | 223,093 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $630.19 | $1.21K |
52-Week Low | $393.42 | $181.60 |
Typical Hold Time | 14 Days | 48 Days |
Enterprise Value | $16.44B | $1.13T |
Dividend Yield | — | 0.06% |
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
Micron Technology (MU) trades at $1,035.84, down 4.79% today, but maintains strong bullish momentum with 500% gains over the past year. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $33.42 versus $31.77, and maintains impressive profitability with 63.8% net income margin. Technical indicators remain bullish overall despite recent pullback, with support at $1,020 and resistance at $1,064. The company's strategic customer agreements covering 35% of revenue through 2030 provide visibility into future growth.
Micron presents compelling investment potential driven by AI memory demand surge and strong financial performance, though risks include cyclical industry exposure and potential growth deceleration. Analyst consensus remains strongly bullish with 82.9% buy ratings and $1,590 price target, representing 53% upside. The stock's valuation at 13.94 P/E appears reasonable given projected revenue growth to $133.2B in 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →